Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.
| Autor: | Clemente B; GSK, Siena, Italy., Denis M; GSK, Siena, Italy., Silveira CP; GSK, Siena, Italy., Schiavetti F; GSK, Siena, Italy., Brazzoli M; GSK, Siena, Italy., Stranges D; GSK, Siena, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2023 Nov 27; Vol. 14, pp. 1294929. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2023). |
| DOI: | 10.3389/fimmu.2023.1294929 |
| Abstrakt: | With the deepening of our understanding of adaptive immunity at the cellular and molecular level, targeting antigens directly to immune cells has proven to be a successful strategy to develop innovative and potent vaccines. Indeed, it offers the potential to increase vaccine potency and/or modulate immune response quality while reducing off-target effects. With mRNA-vaccines establishing themselves as a versatile technology for future applications, in the last years several approaches have been explored to target nanoparticles-enabled mRNA-delivery systems to immune cells, with a focus on dendritic cells. Dendritic cells (DCs) are the most potent antigen presenting cells and key mediators of B- and T-cell immunity, and therefore considered as an ideal target for cell-specific antigen delivery. Indeed, improved potency of DC-targeted vaccines has been proved in vitro and in vivo . This review discusses the potential specific targets for immune system-directed mRNA delivery, as well as the different targeting ligand classes and delivery systems used for this purpose. Competing Interests: All authors are employed by the GSK group of companies. (Copyright © 2023 Clemente, Denis, Silveira, Schiavetti, Brazzoli and Stranges.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|